Vytrus Biotech S.A.

Vytrus Biotech S.A.

VYT · MC · Healthcare / Biotechnology

13.15EUR-0.05 (-0.38%)

Price History

Full chart

Market Stats

Previous Close13.20
Open13.10
Day Range13.10 – 13.35
52-Week Range5.65 – 20.60
Volume660
Market Cap113.12M
P/E (TTM)36.71
Forward P/E0.00
EPS0.41
Dividend Yield0.00%
Beta-0.09
50-Day Avg16.54
200-Day Avg15.13

About

Vytrus Biotech, S.A. develops, produces, and sells active ingredients from plant stem cells in Spain and internationally. It offers Clarivine that activates skin's regeneration processes; Quora Noni biomics for rejuvenating the skin microbiota; Deobiome Noni, a prebiotic deodorant to reduce the generation of body odour; Sarcoslim Re-Shape, an active ingredient to reduce fat on tissue; Capilia Longa that improves density in hair, eyebrows, and eyelashes; and Luminia Granatum that brightens skin, whitens dark spots, evens skin tone, and protects against oxidative stress. The company also provides Baolift that improves muscle tone and facial complexion; Elaya Renova that boosts hair tensegrity; Kannabia Sense, a prebiotic treatment that stimulates the skin microbiota to produce an in-situ postbiotic cocktail; Quora Noni to avoid the attack of skin harmful bacteria; Centella Reversa for facial complexion improvement; and Arabian Cotton to protect and repair cell structures against sun damage. In addition, it offers Photobiome, a prebiotic active that fights the skin photoageing process; Nectaria Lithops, an active ingredient that biophysically optimizes the skin microenvironment and vitamin D levels; Olea Vitae, a cellular oil against ageing; Turmeria Zen for skin hydration and wrinkles on stressed profiles; and Sensia Carota, a plant-based active that protects and prevents from the damage on sensitive and sensitized skins. Further, the company provides technology solutions, such as plasma rich in cell factors; phyto-peptidic, phyto-lipidic, and phyto-glucidic fractions; and phyto-cell fusions, as well as Vytrus TV to create an audiovisual space with added value for cosmetic formulation. It exports its products. Vytrus Biotech, S.A. was incorporated in 2009 and is headquartered in Barcelona, Spain.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Albert Jane Font
  • Employees44
  • Headquarters121 Sant Gaietà, Barcelona, Spain, 08221, Spain
  • Websitehttps://www.vytrus.com

Leadership

  • Mr. Albert Jane FontCo-Founder, Co-CEO, President, Member of Management Board & Director
  • Mr. Oscar Exposito TarresCo-Founder, Co-CEO, C.S.O, Member of Management Board & Director
  • Mr. Jordi Rovira MartinezCFO, Member of Management Board, Secretary of the Board & Director
  • Mr. Daniel RobustilloSales Director & Member of Management Board
  • Mr. Manel LopezCOO & Member of Management Board
  • Ms. Sara LaplanaExecutive CSO & Member of Management Board
  • Gloria RuizAccounting Director
  • Alejandro GuiradoCommunication & Marketing Manager
  • Conxita RusinesESG & People Wellbeing Manager
  • Marta RomeroFinance Controller

Financials

Income Statement

Currency: EUR2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue1.70M2.80M3.68M3.74M5.04M8.37M
Growth (%)-+64.49%+31.31%+1.48%+35.00%+65.95%
Cost of Revenue207.88K423.17K650.74K-611.01K-453.46K-457.32K
Gross Profit1.50M2.38M3.03M4.35M5.50M8.83M
Gross Margin87.81%84.91%82.33%116.35%108.99%105.46%
Operating Expense1.29M1.95M2.39M3.89M4.49M5.65M
Operating Income208.18K429.56K644.70K454.27K1.00M3.18M
Operating Margin12.21%15.32%17.51%12.16%19.92%38.01%
EBITDA--1.34M1.18M1.83M4.16M
EBITDA Margin--36.29%31.56%36.36%49.65%
Net Income216.90K450.02K605.26K544.94K1.02M2.90M
Net Income Margin12.72%16.05%16.44%14.58%20.24%34.60%

Balance Sheet

Currency: EUR2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets6.21M7.18M8.00M9.31M11.13M14.66M
Total Liabilities2.60M2.93M3.25M4.02M3.84M4.35M
Total Equity3.61M4.25M4.75M5.29M7.29M10.31M
Cash1.09M1.28M724.62K1.10M2.53M3.38M
Net Debt-603.20K1.30M1.75M--

Cash Flow

Currency: EUR2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-132.47K447.92K225.55K904.39K1.84M3.90M
Investing Cash Flow-237.72K-302.78K-525.95K---
Financing Cash Flow635.24K45.02K-258.23K---
Capital Expenditure235.33K271.82K494.16K1.17M1.20M2.68M
Free Cash Flow-176.11K-268.62K-261.83K640.24K1.22M
FCF to OCF-39.32%-119.10%-28.95%34.72%31.30%

Key Statistics & Ratios

Market Cap113.12M
Enterprise Value120.36M
Trailing P/E36.71
Forward P/E0.00
Price / Sales11.67
Price / Book11.81
EPS0.41
Book Value1.37
Revenue (TTM)9.69M
Gross Profit (TTM)8.83M
EBITDA3.39M
Profit Margin29.89%
Operating Margin32.87%
Return on Equity32.92%
Return on Assets15.29%
Shares Outstanding7.52M
Shares Float3.77M
Beta-0.09
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%